PSNL vs WGS
PSNL: A genomic testing company enabling precision oncology through ultra-sensitive liquid biopsy and tumor sequencing to detect cancer recurrence and guide personalized treatment decisions. WGS: GeneDx is a genomic intelligence platform using whole-genome sequencing and AI-powered interpretation to diagnose rare diseases, analyze cancers, and support precision medicine across clinical and research settings.
Side-by-side fundamentals
| Metric | PSNL | WGS | Edge |
|---|---|---|---|
| Price as of 2026-07-30 close | $12.28 | $60.54 | |
| Market cap as of 2026-07-31 | $1.3B | $1.8B | |
| PEG as of 2026-07-31 | n/a | -0.30 | |
| Net margin as of 2026-07-31 | -148.1% | -17.6% | WGS higher |
| Gross margin as of 2026-07-31 | +13.7% | +69.6% | WGS higher |
| Operating margin as of 2026-07-31 | -158.9% | -16.4% | WGS higher |
| ROE as of 2026-07-31 | -43.5% | -27.5% | WGS higher |
| ROA as of 2026-07-31 | -32.9% | -15.7% | WGS higher |
| Debt / equity as of 2026-07-31 | 0.00 | 0.38 | PSNL lower |
| Revenue growth (YoY) as of 2026-07-31 | -24.7% | +34.1% | WGS higher |
| Revenue CAGR (3y) SEC XBRL | +2.3% | +22.1% | WGS higher |
| Beta as of 2026-07-31 | 2.18 | 2.01 | |
| 1-year return as of 2026-07-30 close | +119.7% | -24.2% | PSNL higher |
Fundamentals: market data, as of 2026-07-31. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-07-30.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.